



7934 Government Road, Burnaby, B.C., V5A 2E2

Phone: (604) 551-7831 Fax: 604-676-2767

info@cannabixtechnologies.com

cannabixtechnologies.com

Cannabix Technologies Inc. Provides Update on Marijuana Breathalyzer Development

Vancouver, British Columbia, September 9, 2014, 2014 -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company”), developer of the patent pending Cannabix Marijuana Breathalyzer for use by law enforcement to detect THC levels in drivers, is pleased to announce that it has received device renderings from its engineering contractor, KLN Klein Product Development, marking a key step forward in the development of its Cannabix Breathalyzer device.

The company also reports that the Licensor of the Cannabix Marijuana Breathalyzer System has signed a collaboration agreement with Field Forensics Inc. to develop a roadside test kit for use with its Cannabix Marijuana Breathalyzer.

Field Forensics Inc. (“FFI”), a leading developer and manufacturer of forensics sampling and identification devices for law enforcement, homeland security, and military customers worldwide, has begun development of a potential test kit that would be used in combination with Cannabix’s breath testing technology to determine the presence of THC (the psychoactive component of marijuana that causes impairment) at the roadside by law enforcement and in the workplace. FFI produces a host of products including explosives detection, drug detection, and field and laboratory chemical sampling devices in addition to research and development services for defense, security, and law enforcement, and training services in homeland security applications.

Craig Johnson, CEO of Field Forensics Inc. stated, “Cannabix’s unique breath testing technology dovetails well with our solution. We are impressed with Cannabix and their approach to developing a THC detection device for law enforcement. This is definitely a timely device.”

Kal Malhi, President of Cannabix Technologies Inc. stated, “Field Forensics is a high growth, awarding winning, innovative company. Our collaboration is a positive development for Cannabix. FFI’s experience and tremendous network in law enforcement, government and private sector bodes well for Cannabix. Our prototype development is progressing well as we have recently received device renderings from KLN Klein Product Development. The renderings are impressive and our team is pushing along development of our marijuana breathalyzer at a good pace.”

The Company also announces that on September 6th, 2014, Cannabix Technology Inc. (OTC PINK: BLOZF) became “piggyback” eligible for trading in the U.S., whereby authorized market makers can begin quoting a piggy-back eligible security at any point in time.

Cannabix also reports that has filed paperwork with Depository Trust Co. (“DTC”) to facilitate book-entry delivery, depository services and electronic settlement of transfers of its common shares in the United States. The Company will provide a further update if and/or when DTC eligibility has been granted.

About Field Forensics Inc.

Based in St. Petersburg, Florida, Field Forensics Inc. was recently awarded the 2014 *R&D100* Award from the editors of New Jersey based *R&D Magazine*. The *R&D100 Award* is an international competition that recognizes the 100 most technologically significant products introduced into the marketplace over the past year. The *R&D100 Awards* recognize excellence across a wide range of industries, including telecommunications, optics, high-energy physics, materials science, chemistry and biotechnology.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is the developer of the patent pending Cannabix Marijuana Breathalyzer for law enforcement. The Cannabix Marijuana Breathalyzer drug-impairment recognition system is based on breath testing technology that has been developed in Sweden that has been clinically researched to be successful in testing individuals for recent consumption of the THC component of marijuana. Cannabix Technologies Inc. is advancing its products to enable law enforcement personnel to use this technology to enhance detection of marijuana impaired driving offences on North American roads at a time when marijuana is becoming legal in various jurisdictions. Cannabix Technologies Inc. is working to develop the Cannabix Breathalyzer device that will detect Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) using breath samples. The device will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company's CEO, Rav Mlait 604-551-7831 email at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.